Anti diabetuc drug for 10 marks

Reading File

Finding Sources

Reading File

I now have very rich content from Goodman & Gilman. The truncated output included a wealth of information about sulfonylureas, meglitinides, GLP-1 agonists, DPP-4 inhibitors, SGLT2 inhibitors, metformin, and more. Let me now compose a thorough 10-mark exam answer.

Antidiabetic Drugs - 10 Mark Answer

Antidiabetic drugs are classified into two broad categories: insulin and oral/injectable non-insulin agents. Their choice depends on the type of diabetes, degree of glycemic control needed, comorbidities, and side-effect profile.

Classification

A. Insulin

Type	Examples	Onset / Duration
Ultra-rapid acting	Insulin lispro, aspart, glulisine	15 min / 3-5 h
Short-acting (Regular)	Soluble insulin	30-45 min / 6-8 h
Intermediate-acting	NPH (isophane)	1-2 h / 12-18 h
Long-acting	Insulin glargine, detemir, degludec	1-2 h / 24+ h

B. Oral / Injectable Non-Insulin Agents

Biguanides - Metformin
Sulfonylureas (SUs) - Glibenclamide, Glipizide, Glimepiride
Meglitinides / Glinides - Repaglinide, Nateglinide
Thiazolidinediones (TZDs) - Pioglitazone, Rosiglitazone
Alpha-glucosidase inhibitors - Acarbose, Miglitol
DPP-4 inhibitors (Gliptins) - Sitagliptin, Saxagliptin, Vildagliptin
GLP-1 receptor agonists - Liraglutide, Semaglutide, Exenatide
SGLT2 inhibitors (Gliflozins) - Empagliflozin, Dapagliflozin, Canagliflozin
Amylin analogue - Pramlintide

1. Insulin

Mechanism: Binds insulin receptor (tyrosine kinase receptor) on cell membrane, activates glucose uptake (GLUT4 translocation in muscle/fat), inhibits hepatic gluconeogenesis, promotes glycogen synthesis, inhibits lipolysis.

Preparations:

Short-acting analogues (lispro, aspart, glulisine): Modified at B-chain positions to prevent hexamer formation; injected 15 min before meals; lower postprandial hypoglycemia risk vs regular insulin.
Regular insulin: Injected 30-45 min before meals; given IV in emergencies (DKA, surgery, labor).
Glargine: Two arginine residues added at B-chain C-terminus; clear solution at pH 4.0, forms microprecipitate at neutral subcutaneous pH; flat 24 h profile; cannot be mixed with short-acting insulins.

Uses: Type 1 DM (mandatory), Type 2 DM (when oral agents fail), gestational DM, DKA/HHS, perioperative period, hospitalized patients.

ADR: Hypoglycemia (most important), lipodystrophy at injection site, weight gain, insulin resistance (with high doses), insulin oedema.

2. Metformin (Biguanide)

Mechanism:

Activates AMPK (AMP-activated protein kinase) by inhibiting mitochondrial Complex I.
Reduces hepatic gluconeogenesis and glycogenolysis (primary effect).
Improves peripheral insulin sensitivity.
Slows intestinal glucose absorption.
Does NOT cause hypoglycemia (no insulin secretion).

Pharmacokinetics: Not protein bound; excreted unchanged by kidney; t½ ~6 h.

Uses: First-line drug for Type 2 DM; also used in PCOS, pre-diabetes.

ADR: GI disturbances (nausea, diarrhea - most common), lactic acidosis (rare but serious - contraindicated in renal failure, hepatic failure, alcohol excess, contrast media use), vitamin B12 deficiency with long-term use.

Contraindications: eGFR <30 mL/min, hepatic failure, severe heart failure, alcoholism.

3. Sulfonylureas (SUs)

Mechanism: Bind to SUR1 subunit of K_ATP channels on pancreatic β-cells → channel closure → membrane depolarization → Ca²⁺ influx → insulin secretion. Require functioning β-cells.

Examples:

1st generation: Tolbutamide, Chlorpropamide (largely obsolete)
2nd generation: Glibenclamide (glyburide), Glipizide, Glimepiride (preferred)

Pharmacokinetics: Well absorbed orally; highly protein bound; metabolized by liver; excreted by kidney (glibenclamide) or bile.

Uses: Type 2 DM, especially in non-obese patients.

ADR: Hypoglycemia (prolonged, especially with glibenclamide in elderly/renal failure), weight gain, disulfiram-like reaction (chlorpropamide), hyponatremia (chlorpropamide - SIADH).

4. Meglitinides (Glinides)

Mechanism: Like SUs, block K_ATP channels on β-cells → insulin secretion, but bind at a different site on SUR1. Short-acting; taken with each meal ("prandial glucose regulators").

Examples: Repaglinide (benzoic acid derivative), Nateglinide (D-phenylalanine derivative).

Advantage over SUs: Shorter duration → less interprandial hypoglycemia; useful when meals are irregular.

ADR: Hypoglycemia (less than SUs), weight gain.

5. Thiazolidinediones (TZDs / Glitazones)

Mechanism: Agonists of PPAR-γ (peroxisome proliferator-activated receptor gamma) in adipose tissue → increased GLUT4 expression → improved insulin sensitivity in muscle and fat; reduce hepatic glucose output.

Examples: Pioglitazone (preferred), Rosiglitazone.

ADR: Weight gain, fluid retention/oedema, heart failure (contraindicated in NYHA class III-IV), fractures (especially in women), bladder cancer risk (pioglitazone - long term).

Note: Rosiglitazone withdrawn in many countries due to increased cardiovascular risk.

6. Alpha-Glucosidase Inhibitors

Mechanism: Competitively inhibit intestinal alpha-glucosidases (maltase, sucrase, glucoamylase) → delay carbohydrate digestion and glucose absorption from gut → reduce postprandial hyperglycemia.

Examples: Acarbose, Miglitol, Voglibose.

ADR: Flatulence, bloating, diarrhea (due to undigested carbohydrates fermenting in colon - most common complaint). No systemic hypoglycemia alone. If hypoglycemia occurs (when combined with insulin/SUs), must treat with glucose (not sucrose, as sucrase is inhibited).

7. DPP-4 Inhibitors (Gliptins)

Mechanism: Inhibit dipeptidyl peptidase-4 enzyme → prevent degradation of endogenous GLP-1 and GIP (incretins) → increased incretin levels → glucose-dependent insulin secretion + inhibition of glucagon.

Examples: Sitagliptin, Saxagliptin, Vildagliptin, Alogliptin, Linagliptin.

Advantage: Weight-neutral; low hypoglycemia risk; can be used in renal impairment (linagliptin - hepatic elimination).

ADR: Nasopharyngitis, upper respiratory infections, pancreatitis (rare), urinary tract infections. Saxagliptin associated with increased heart failure hospitalization.

8. GLP-1 Receptor Agonists

Mechanism: Mimic endogenous GLP-1 → stimulate insulin secretion in a glucose-dependent manner → suppress glucagon → slow gastric emptying → reduce appetite (central effect).

Examples:

Short-acting (daily): Exenatide, Liraglutide
Long-acting (weekly): Semaglutide, Dulaglutide, Albiglutide

Advantages: Weight loss (significant), reduce cardiovascular mortality and MI (liraglutide, semaglutide - proven in LEADER and SUSTAIN trials), no hypoglycemia when used alone.

ADR: Nausea, vomiting (most common), pancreatitis, medullary thyroid carcinoma (C-cell tumors - contraindicated with personal/family history of MTC or MEN 2).

9. SGLT2 Inhibitors (Gliflozins)

Mechanism: Inhibit sodium-glucose cotransporter 2 (SGLT2) in proximal convoluted tubule of kidney → prevent glucose reabsorption → glycosuria → reduces blood glucose. Also causes natriuresis.

Examples: Empagliflozin, Dapagliflozin, Canagliflozin.

Additional benefits:

Reduce body weight and blood pressure.
Reduce cardiovascular mortality and hospitalization for heart failure (empagliflozin - EMPA-REG trial; dapagliflozin - DAPA-HF trial) - approved in heart failure with and without DM.
Slow progression of chronic kidney disease.

ADR: Genital mycotic infections (candidiasis - most common), urinary tract infections, polyuria, euglycemic DKA (rare, serious), Fournier's gangrene (rare), volume depletion/hypotension, fractures (canagliflozin).

Summary Table

Drug Class	Mechanism	Hypoglycemia	Weight	Key ADR
Metformin	↓ Hepatic gluconeogenesis (AMPK)	No	Loss	Lactic acidosis, GI upset
Sulfonylureas	K_ATP block → insulin secretion	Yes	Gain	Prolonged hypoglycemia
Meglitinides	K_ATP block (prandial)	Mild	Gain	Less hypoglycemia than SUs
TZDs	PPAR-γ agonist	No	Gain	Oedema, heart failure
Alpha-glucosidase inhibitors	Delay carb absorption	No	Neutral	Flatulence, bloating
DPP-4 inhibitors	↑ Incretin levels	No	Neutral	URTI, pancreatitis
GLP-1 agonists	GLP-1 receptor activation	No	Loss	Nausea, pancreatitis
SGLT2 inhibitors	Glucosuria	No	Loss	Genital infections, DKA

Current Treatment Algorithm (ADA Guidelines)

Type 2 DM: Metformin is first-line (unless contraindicated).
Add SGLT2 inhibitor or GLP-1 agonist if established CVD, heart failure, or CKD.
Add DPP-4 inhibitor, SU, or TZD as second/third line based on cost, tolerability.
Insulin when HbA1c targets not met with oral agents.

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Ed.; Katzung's Basic and Clinical Pharmacology, 16th Ed.

This is a shared conversation. Sign in to Orris to start your own chat.